Clinical Trial Update: TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial results comparing TMC435HPC3001 with telaprevir, both given with pegylated interferon alfa-2a and ribavirin, in chronic hepatitis C patients who w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• TMC435
• Telaprevir (telaprevir)

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-04-10